GPCM
SPRB

Granite Point Capital Management’s Spruce Biosciences SPRB Stock Holding History

Granite Point Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-848
Closed -$382K – 160
2021
Q3 		$382K Sell
848
-485
-36% -$305K 0.03% 119
2021
Q2 		$1.12M Hold
1,333
– – 0.04% 112
2021
Q1 		$1.66M Hold
1,333
– – 0.06% 106
2020
Q4 		$2.43M Buy
+1,333
New +$2.21M 0.12% 79

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Granite Point Capital Management's SPRB Position: Q4 2021 in Review

Granite Point Capital Management sold out of Spruce Biosciences (SPRB) in Q4 2021, closing a stake of 848 shares — an estimated $382K sold.

Granite Point Capital Management first reported a position in SPRB in Q4 2020 and held it in 4 quarters. The position peaked at $2.43M in Q4 2020. 50 funds tracked by Wall St. Rank hold SPRB as of Q4 2021.

  • Granite Point Capital Management reported no remaining Spruce Biosciences position as of Q4 2021 after selling out during the quarter.
  • Granite Point Capital Management sold 848 Spruce Biosciences shares in Q4 2021, an estimated $382K.
  • Granite Point Capital Management first reported a position in Spruce Biosciences in Q4 2020 and held it in 4 quarters.
  • Granite Point Capital Management's Spruce Biosciences position peaked at $2.43M in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Spruce Biosciences as of Q4 2021.

Based on Granite Point Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.